Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00999154
Other study ID # 090238
Secondary ID 09-DK-0238
Status Terminated
Phase
First received
Last updated
Start date September 19, 2009
Est. completion date October 22, 2012

Study information

Verified date October 22, 2012
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- Obesity is the result of many factors, including genetics and lifestyle, such as over-eating high-calorie foods and not being physically active. Obesity affects approximately one third of adults in the United States. Researchers often study individuals who are already overweight and obese, but another approach is to examine people who stay thin despite eating whatever they want and not exercising. Studying these thin individuals will enhance understanding of why some people become obese and others do not, which may lead to novel treatments for obesity.

Objective:

- To study the metabolism, body composition, body temperature, physical activity, and blood chemistries of healthy lean adults before and after adding 1,000 extra Calories per day to their normal diet.

Eligibility:

- Healthy adults, 30 to 50 years of age, who have never been overweight after adolescence, who are currently weight-stable, sedentary, and eating without restrictions.

Design:

- The entire study will take about 9 weeks and will include the following outpatient and inpatient visits:

<TAB>- Outpatient screening visit and monitoring: Physical examination and blood test at screening; then, one week of physical activity monitoring (e.g., with a pedometer-like device called an accelerometer) and completing a food diary.

<TAB>- Baseline inpatient visit (5 days): Volunteers will eat a normal diet to maintain body weight. Energy expenditure, body composition, physical fitness, activity level, and eating behavior will be measured. Urine and blood samples will be taken. Volunteers may go home for the weekend or stay at the metabolic clinical research unit (MCRU).

<TAB>- Inpatient feeding week 1 (5 days): Volunteers will eat a normal diet plus milkshakes for added calories. All the same measurements during the baseline week visit will be repeated.

<TAB>- Outpatient feeding weeks 2 3: Volunteers will eat breakfast at the MCRU everyday for the next 2 weeks and take prepared meals home with them (volunteers may also stay at the MCRU for the 2 weeks if they prefer). Volunteers will drink a non-radioactive (heavy) water called doubly labeled water to measure energy expenditure in their normal living environment Daily urine samples will be collected.

<TAB>- Inpatient feeding week 4 (5 days): Volunteers will continue eating a normal diet plus milkshakes for added calories. This stay and measurement is identical to inpatient feeding week 1.

- Volunteers will be contacted at 6 and 12 months to assess any changes in body weight, diet, and physical activity.


Description:

While many obesity studies focus on the individuals who are already overweight and obese, a complementary approach to understand such a common disease is to define the mechanisms which allow some lean individuals to resist weight gain. The predominant cause of human obesity is the inheritance of genes favoring fat storage and efficient energy utilization interacting with an obesogenic environment, characterized by readily available, energy-dense food and sedentary lifestyle. However, a persistent percentage (about 30%) of the US adult population remains thin (BMI <23 kg/M(2)). While some of these individuals maintain their weight by vigilantly controlling their diet, exercising or taking medication(s), others may have the ability to remain thin despite an excessive energy intake and without volitional exercise. To identify these individuals and define their phenotypes will provide unique insights into energy and body weight homeostasis, and may yield novel approaches for treating obesity.

In this natural history protocol, we will recruit and characterize a cohort of constitutionally lean and healthy adult volunteers (age 25-50, BMI 18.5-25 kg/M(2)) who do not have pathological or exogenous factors that are known to stimulate energy expenditure, suppress food intake, or decrease absorption. We will recruit volunteers who are weight-stable, sedentary, and non-restrictive eaters, characterize their free-living dietary and physical activity energy expenditure using food records and portable accelerometers, respectively. Using an inpatient controlled setting, we will carefully characterize the details of their 24-hr energy metabolism, body composition, core and skin temperatures, and blood chemistries while they are on a one-week metabolic diet adjusted to maintain his/her body weight (baseline) vs. another week of higher energy intake level (1000 extra kcal per day above their baseline). Overfeeding will continue for two more weeks in the outpatient setting with all meals provided by our metabolic kitchen, followed by the fourth week of overfeeding and repeated measurements back in the inpatient setting. We hypothesize that spontaneous changes in energy expenditure and/or calorie intake may differ between individuals, and such difference may explain the ability for some to resist body gain. The accruals of humans with obesity-resistant phenotypes will significantly enhance our understanding of the mechanisms of energy homeostasis and identify potential novel regulators for controlling obesity.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date October 22, 2012
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 25 Years to 50 Years
Eligibility - INCLUSION CRITERIA:

1. Healthy normal men and women between 25-50 years of age;

2. BMI between 18.5 and 25.0 kg/M(2);

3. Self-reported as having had trouble gaining weight, who doing little or no exercise, self-described or by friends or family members as an overeater, and who have never tried to lose weight.

EXCLUSION CRITERIA:

1. A self-reported history of overweight after the age of 18, other than during pregnancy for women;

2. Recent weight changes >2% of current body weight in the last 6 months;

3. Current or past history of eating disorders such as binge eating, anorexia nervosa, or bulimia, by psychological evaluations;

4. Current or past history of intentional weight loss by self-report, other than postpartum weight loss;

5. High physically demanding occupations or volitional exercise >20 total minutes/day of moderate intensity or higher (as measured by sweating), >2 days/week, by self-report;

6. Significant dietary limitations (multiple food allergies/intolerances, vegan diet, etc.) that may affect absorption and body weight, or special dietary requirements that are difficult to accommodate with by study diets;

7. Significant physical limitations that may preclude completing the majority of the tests in this study;

8. Current pregnancy, recent pregnancy (<3 years), current/recent breast feeding (<1 year), or perimenopausal status. During the study, women may be asked to use birth control and will undergo repeated pregnancy testing. Subjects who refuse these tests will be excluded;

9. Current or past medical conditions that are known to affect energy metabolism and body weight regulations, including HIV/AIDS, cancer, cardiac ischemia, dyslipidemia, thyroid and parathyroid disorders, hypo- or hypertension, diabetes (type 1 or type 2) or impaired glucose tolerance, congenital or acquired lipodystrophy, hepatic, renal, neuromuscular, celiac disease and other malabsorptive conditions, known genetic disorders that alter lipid metabolism, or cardiac failure as assessed by history and physical exam;

10. Any psychiatric condition (including psychosis) or personality disorder as judged by the PI or Co-PI that would impede participation in the study;

11. Smoking (currently or within the past year), excessive caffeine (>500 mg/day) and/or alcohol intake (>2 drinks/day for men, > 1 drink/day for women), as assessed by self reports and serum thiocyanate;

12. Taking narcotics, cocaine, or marijuana which would alter metabolism (positive urine toxicology screen)

13. Any use of medications or nutritional supplements known to increase EE, depress food intake, or affect absorption;

14. Unwilling or unable to give informed consent;

15. Any other clinical or sub-clinical conditions not mentioned above that are considered by the investigators as significant exclusions for the study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Coleman DL. Obesity genes: beneficial effects in heterozygous mice. Science. 1979 Feb 16;203(4381):663-5. — View Citation

Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998 May 29;280(5368):1374-7. Review. — View Citation

Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006 Apr 5;295(13):1549-55. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1